Epidural steriod injections (ESIs) are commonly used for managment of lumbosacral radiculopathy (LSR). Predicting outcomes after ESIs could be another valuable application of needle electromyography (EMG) in these patients.
Introduction
Lumbosacral radiculopathy (LSR) is one of the most common disorders evaluated by neurologists and a common cause of referral for electrophysiological assessment [1] . Etiology of LSR includes nerve root compression from pathology in the intervertebral disc, such as a prolapsed lumbar intervertebral or surrounding structures, spondylolisthesis, facet joint arthropathy, or synovial cysts [2] . It may also occur as a result of diversity of lesions including infectious, inflammatory, and neoplastic disorders [3] . Patients might present with pain, numbness, and weakness or any of these symptoms [2] . Pain is commonly in the form of back pain radiating into the leg and exacerbated by back flexion or extension, sitting, coughing, or straining and relieved by lying down or sometimes walking [1] .
There is no gold standard for the diagnosis of LSR. Accordingly, a combination of history, physical examination, imaging, and electrodiagnostic testing is used to reach diagnosis of LSR [4] . Needle electromyography (EMG) is commonly used to assess muscle activity and integrity of the neuromuscular system. Therefore, it can help in determining if there is axonal injury of the motor nerve fibers or roots supplying muscles [5] .
However, epidural steroid injection (ESI) is a common treatment option for patients complaining of low back pain and sciatica. It is indicated for treating radicular and low back pain caused by herniated disc, chemical neuritis, and spondylosis. ESIs are most effective during the acute phase of pain and inflammation [8] . Radicular pain is more likely to respond to ESIs than back pain. Response rates reaches up to 90% in patients with symptoms duration less than 3 months and may fall under 50% in patients with symptoms more than a year. A poor response rate is predicted by prior lumbar surgery, severe compression spinal stenosis, and/or a large herniated disc [9] .
The three routes of entry to the epidural space are caudal, interlaminar, and transforaminal. All are actively practiced today and have their own unique risks and benefits [10] . Transforaminal ESI has been developed only in the past 10-15 years and is designed to administer the most target specific agent in the affected root. Recent outcome studies reveal greater duration of pain relief and avoidance of surgery compared with interlaminar injections [11] [12] [13] .
The usefulness of EMG as a predictive tool for the success of ESI is still controversial. A review of the literature revealed few recent studies [2, [14] [15] [16] [17] ] that evaluated the usefulness of EMG in predicting pain and functional improvement after ESI. For predicting outcomes after ESI, needle EMG could be a valuable tool to identify appropriate patients for ESI.
Aim
The aim of this study was to determine if EMG studies can predict pain reduction and improve functional outcome after transforaminal ESIs in patients with LSR.
Materials and methods
This study included 20 patients complaining of low back pain and sciatica owing to LSR. Participants were included in the study if they fulfilled the following criteria [2, 18] :
(1) Presenting history and pain diagram demonstrating LBP radiating down the lower limb in the distribution of L4, L5, or S1 dermatomes.
(2) MRI demonstrating nerve impingement of the L4, L5, and/or S1 nerve roots. (3) Physical examination consistent with radicular irritation or neurological findings of sensory, motor, and/or reflex abnormalities in the L4, L5, or S1 nerve root distribution. (4) Duration of symptoms 12 months or less.
Patients with LSR who do not respond to conservative care (including anti-inflammatory medications, analgesic drugs, life style modification, and/or physical therapy) were selected for transforaminal ESI [19] .
Exclusion criteria for epidural steriod injection
Patients who were not candidates for epidural injection were those having the following:
(1) Symptoms requiring early surgical treatment (severe motor weakness, cauda equina syndrome, or hyperalgic sciatica). The nature of the present study was explained to all patients. Verbal and written consents were obtained from all patients. Research protocol was approved by the Ethical Committee of Faculty of Medicine, Alexandria University.
Baseline evaluation before injection
Thorough history taking and clinical examination were performed to determine root level affection and laterality of LSR. In addition, MRI was done for all studied patients to assist, with clinical examination, in proper selection of the affected root levels for injection.
Electrodiagnostic studies [20] were performed for all the studied patients bilaterally and included the following: motor nerve conduction studies (for posterior tibial and common peroneal nerves), late responses (tibial F-wave and gastrosoleus H-reflex), and mixed and dermatomal somatosensory-evoked potentials (SSEP) over the dermatomal territory of L4, L5, and S1 roots. Needle EMG [20] was performed, and the examined muscles were selected according to the affected nerve roots. Recording of muscle activity was done at rest (sensitivity was set at 50 μV/division, and analysis time was 100 ms), minimal volition (the sensitivity was set at 200 μV/ division, and analysis time was 100 ms), and maximal volition (the sensitivity was set at 200 μV/division, and analysis time was 1 s). Sensory nerve conduction studies (for sural and superficial peroneal nerves) were done bilaterally to exclude peripheral neuropathy.
Parameters assessed in patients before injection included pain assessment using numerical visual analog scale (VAS) [21] and assessment of functional status by Oswestry disability index (ODI) [22] .
Transforaminal epidural steroid injection
All participants were then scheduled to undergo a transforaminal ESI of methylprednisolone under fluoroscopic guidance at the suspected level of pathology. The injection site and level of injection were determine by MRI results and supported by dermatomal clinical examination.
All injections were performed as outpatient procedures. With the patient lying prone, a wide area of the back was exposed and disinfected. Transforaminal ESI was conducted under biplane fluoroscopic guidance. The classic injection site underneath the pedicle in the 'safe triangle' [9, 23] . With fluoroscopic guidance, 12-cm, 22-G spinal needle was then advanced into the safe triangle. The needle position was checked using biplane fluoroscopy followed by injection of 1 ml contrast material. Posteroanterior and lateral spot radiographs were obtained to document contrast material distribution. Bupivacaine hydrocholoride (0.5 ml/ 0.5%, marcaine spinal 0.5% heavy; AstraZeneca, USA) and 40 mg (1 ml) of methylprednisolone acetate were slowly injected.
To check the effect of the transforaminal ESI, all patients were asked to refrain from drug or physical therapy for sciatica over the 2-week period after injection.
Follow-up evaluation 2 weeks after epidural steriod injection
Primary outcome measures were assessed in patients 2 weeks after the injection, and they included pain assessment using VAS and assessment of functional status by ODI.
Secondary outcomes were greater than 50% improvement in VAS for pain and in functional score (ODI).
Statistical analysis
Data were analyzed using the statistical package for the social sciences (SPSS ver. 20; SPSS Inc., Chicago, Illinois, USA). The distribution of quantitative variables was tested for normality per group using Kolmogorov-Smirnov test, which revealed that the data are not normally distributed. Quantitative data were described using median and range whereas qualitative data were described using number and percentage. Mann-Whitney U-test was used to compare quantitative parameters between the two groups. Kruskal-Wallis test was used to compare quantitative parameters between the three groups. Linear regression model was used to predict percentage improvement in pain score and ODI score. Significant predictors detected by univariate analysis were entered in the model by Enter method, and the model was assessed using F-test and r 2 . In all statistical tests, level of significance used was 0.05, below which the results were considered to be statistically significant.
Results
This study included 20 patients, with eight males and 12 females. Their mean age was 42.60±10.94 years, and median age was 44 years, ranging between 25 and 68 years. They complained of low back pain and sciatica owing to LSR. Seven patients were complaining of right sciatica and 13 patients were complaining of left sciatica.
The mean duration of symptoms was 5.25±2.97 months, median was 5.5 months, ranging from 1 to 10 months. Seven (35%) patients had disease duration less than 3 months, four (20%) patients had disease duration 3-6 months, whereas nine (45%) patients had disease duration greater than 6 months.
On the clinical level, all cases were diagnosed as unilateral radiculopathy. One patient had L4 radiculopathy, three patients had L5 radiculopathy, five patients had S1 radiculopathy, two patients had L4, 5 radiculopathy, three patients had L5, S1 radiculopathy, and six patients had L4, 5, S1 radiculopathy. This was supported by MRI findings, which have shown similar root level affection. Table 1 demonstrates peripheral electrodiagnostic studies of both lower limbs. According to normal values obtained from literature, none of the studied patients had abnormalities in the peripheral motor, sensory conduction studies and/or late responses. Mixed and dermatomal SSEP mean latencies of the studied patients are presented in Table 2 . According to SSEP, seven patients had single-level radiculopathy and 13 patients had multiple-level affection.
There were statistically significant decrease in pain severity (P=0.001) and improvement in functional score after injection (P=0.001; Table 3 ).
The mean percentage of improvement in pain severity (VAS) was 63.51±22.16, ranged between 0 and 100, and the median was 64.55. The mean percentage of improvement in ODI was 63.68±23.29, ranged between 0 and 93.5, and the median was 64.25.
One of the outcome measures in the current study was the percentage of patients who achieved greater than 50% improvement in VAS for pain and in functional score (ODI). Sixteen (80%) patients achieved greater than 50% improvement in VAS whereas 17 (85%) patients achieved greater than 50% improvement in functional score by ODI. Patients were categorized as responders (who achieved >50% improvement in pain and function) and nonresponders (<50% improvement in pain and function).
Patients with symptom duration less than 3 months showed significant decrease in pain (P=0.022) and improvement in function (P=0.029) after injection compared with patients with longer duration of symptoms (Table 4) .
Pain severity and functional outcome after ESI were not affected by the number of root level affection determined by somatosensory evoked potential (SEP) ( Table 5 ).
Needle EMG study done before injection demonstrated that 13 patients had negative EMG findings and seven patients had positive findings in the form of abnormal rest potentials, neuropathic motor unit action potentials, or abnormal interference pattern. Patients with negative EMG findings showed significant decrease in pain severity (P=0.001) and improvement in functional score (P=0.001) after injection compared with EMG positive group (Table 6 ). Regression analysis showed that negative needle EMG findings were significant predictors of decrease in pain (P=0.001) and improvement in functional outcome (P=0.002) in patients after ESIs (Table 7 ).
Discussion
The current study was initiated to determine if EMG studies can predict functional outcomes in patients with LSR undergoing transforaminal ESI. This study included 20 patients, comprising 12 (60%) CMAP, compound muscle action potential; CV, conduction velocity; DL, distal latency; PL, peak latency; SNAP, sensory nerve action potential. females and eight (40%) males, with mean age of patients of 42.60±10.94 years.
In the current study, 16 (80%) patients achieved greater than 50% improvement in pain, whereas 17 (85%) patients achieved greater than 50% improvement in functional score. Patients were categorized as 'responders' and 'nonresponders' to be consistent with prior studies [7, 24] [29] .
In the current study, shorter duration of symptoms was a reliable determinant of better outcome compared Significance between groups P 1 =1.000; P 2 =0.005*; P 3 =0.217
Significance between groups was done using Mann-Whitney test. KW χ 2 , χ 2 for Kruskal-Wallis test; ODI, Oswerty disability index; P 1 , P value for comparing between groups (<3 months and 3-6 months); P 2 , P value for comparing between groups (<3 months and >6 months); P 3 , P value for comparing between groups (3-6 months and >6 months); VAS, visual analog scale. *P≤0.05, statistically significant.
with longer symptom duration. This was in agreement with Lee et al. [26] who found that treatment was more effective in patients with sciatica of less than 6-month duration (acute or subacute) than in those with sciatica of greater than 6-month duration (chronic), but this difference lacked statistical significance. Similarly, Cooper et al. [30] found that patients with acute symptoms experience higher success rates than those with symptoms greater than 3-month duration. Accordingly, the duration of symptoms before the procedure was found to be the best factor for predicting infiltration efficacy of ESI [29] . Vad et al. [31] reported the negative effect of a long pain duration of over 1 year in two patients on the outcome. In 69 patients with disc herniation, Lutz et al. [7] found that patients with a preinjection symptom duration of more than 24 weeks did not respond favorably. Karppinen et al. [27] reported 45% decrease in leg pain after 2.4 months mean pain duration, and Ng et al. [25] reported only 25% in more chronic patients (16.9 months).
The poor outcome of longer duration of symptoms could be explained by chronic compression resulting in microvascular injury that can result in nerve root ischemia, edema, and demyelination. Irreversible neurophysiologic changes related to chronic inflammation, including irritation, may take place with chronic neural compression. These changes might render the nerve root refractory to management with the local steroid injection [29] . Accordingly, it could be suggested that in treating patients with radiculopathy, we should be applying these treatments early in the course of the disease to change long-term outcome.
The results of the current study showed that negative EMG findings were predictive of greater improvement in pain and functional scores compared with positive findings. This could be explained by the fact that EMG is a study of the motor nerves, and abnormal EMG findings (positive EMG) suggest motor nerve dysfunction. This indicates that the radiculopathy is more advanced than in patients with negative EMG findings. More severe cases (with positive EMG) would be less likely to respond to ESI than the less severe groups (with pain and sensory dysfunction only and negative EMG). Accordingly, EMG findings can help in selecting the subset of patients likely to have favorable functional outcome after ESI. reduction after ESI regarding the presence or absence of myotomal spontaneous activity.
Future studies on a larger scale should be done to verify the predictive value of EMG on outcome of transforaminal ESI as well as to study psychological factors and medications that could augment the response to ESI. In addition, similar studies with long follow-up period (3-6 months) should be done to assess the long-lasting effect of ESI.
Conclusion
It can be concluded that negative EMG findings is a significant predictor of pain reduction and functional improvement in patients with LSR undergoing ESI. In addition, shorter symptom duration is a reliable determinant of significant improvement in pain severity and functional score after ESI compared with longer symptom duration.
Accordingly, transforaminal ESI is recommended early in the course of the LSR for better outcome. Needle EMG is recommended before ESI to predict outcomes and help to guide treatment decisions.
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